#FDA approval

Two automated systems are now available to prevent hair loss during chemotherapy.

Pembrolizumab approved for uncommon lymphoma mostly seen in young adults.

Bevacizumab approved for women with Stage III or IV cancer after surgery.

We learn through scientific advances, but also by listening to patients.

Immunotherapy receives accelerate approval for women whose cancer progresses or relapses after chemotherapy.

Prices should be able to adjust to reflect the value in how medicines are prescribed and the outcomes they deliver.

Approval was based on improves progression-free survival in the MURANO trial.

Oncologists are excited about the increased options available to patients, and about the promise of even more new therapies to come.

Novel drugs targeting unmet needs often don’t follow the traditional three phases of clinical trials.

Enhancing generic competition is an effective way to promote access to needed medicines.

People who received the combination treatment had a statistically significant improvement in relapse-free survival.

However, a recent randomized controlled trial found evidence that the vaccine may prevent oral infections in this population.

Osimertinib led to improved progression-free survival in people with common EGFR mutations.

Dual checkpoint inhibitors improve response rate and survival for people with intermediate or poor risk.

Study showed patients receiving rucaparib had significant improvement in progression-free survival.

FDA will work in close partnership with patients to incorporate their experience into benefit-risk assessments.